ApoB Test Could Refine Heart-Risk Assessment Beyond LDL
A recent JAMA study suggests that the apolipoprotein B (apoB) test, which counts harmful cholesterol particles, may identify people at risk for heart attack or stroke more accurately than standard LDL measurements; using apoB to guide when to intensify statin therapy could prevent more cardiovascular events, but it should be used as an additive tool alongside the regular lipid panel, especially for those with diabetes, obesity, metabolic syndrome, or high triglycerides.
